• Acurx highlighted new mechanistic findings on its antibiotic candidate ibezapolstat, presented June 11, 2026 at the LED3 scientific conference.
• The work supports a selective, targeted mechanism against Gram-positive bacteria, reinforcing the drug’s potential positioning in hard-to-treat infections.
• Ibezapolstat remains slated to advance into international pivotal Phase 3 trials for C. difficile infection, a key value driver for the program.
• The update also underpins earlier-stage efforts to expand into additional Gram-positive indications, including a planned oral program for ABSSSI.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY84505) on June 16, 2026, and is solely responsible for the information contained therein.